RTTNews | Jul 22, 2021 11:10AM EDT

11:09 Thursday, July 22, 2021 (RTTNews.com) - NRx Pharmaceuticals, Inc. (NRXP) shares are rising more than 31 percent on Thursday morning after the company announced first successful commercial formulation of Zyesami or aviptadil for intravenous use in COVID-19 patients.

The company said the original RLF-100 formulation and manufacturing method had only a few weeks of stability, leaving hospitals unable to stock in pharmacies, and leaving aviptadil out of consideration for national strategic stockpiles.

Currently, shares are at $13.34, up 31.95 percent from the previous close of $10.11 on a volume of 7,351,411. For the 52-week period, the shares have traded in a range of $8.39-$76.99 on average volume of 1,328,658.

Read the original article on RTTNews ( https://www.rttnews.com/3211199/nrx-pharma-gains-31-on-first-commercial-formulation-of-zyesami-for-covid-19.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved